Clinical trial

A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated…

NCT00266253 · Hoffmann-La Roche, Industry · Completed

Key facts

NCT number NCT00266253
Title A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin
Official title A Randomized Double-blind Study to Determine the Effect of GK Activator (2) on Efficacy (HbA1c), Safety, Tolerability and Pharmacokinetics in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin.
Lead sponsor Hoffmann-La Roche, Industry
Status Completed
Phase Phase 2
Study type Interventional
Conditions Diabetes Mellitus Type 2
Intervention type Drug
Interventions GK Activator (2), Metformin
Enrollment 220
Start date Nov 1, 2005
Primary completion Mar 1, 2007
Completion Mar 1, 2007
First posted Dec 16, 2005
Last update posted Nov 2, 2016
Countries Australia, Canada, Germany, Spain, United Kingdom, United States

At a glance

  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies